[1]胡　鑫,朱　娜,王　琴.NSCLC患者血清miR-23a和miR-29a水平表达对靶向治疗效果的预测价值[J].现代检验医学杂志,2022,37(02):61-65.[doi:10.3969/j.issn.1671-7414.2022.02.013]
　HU Xin,ZHU Na,WANG Qin.Predictive Value of Serum miR-23a and miR-29a Levels in Patients with NSCLC for Targeted Therapy[J].Journal of Modern Laboratory Medicine,2022,37(02):61-65.[doi:10.3969/j.issn.1671-7414.2022.02.013]
点击复制

NSCLC患者血清miR-23a和miR-29a水平表达对靶向治疗效果的预测价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
61-65
栏目:
论　著
出版日期:
2022-03-15

文章信息/Info

Title:
Predictive Value of Serum miR-23a and miR-29a Levels in Patients with NSCLC for Targeted Therapy
文章编号:
1671-7414（2022）02-061-05
作者:
胡　鑫; 朱　娜; 王　琴
（解放军庐山康复疗养中心/ 原解放军171 医院呼吸内科，江西九江332000）
Author(s):
HU Xin;  ZHU Na;  WANG Qin
（Department of Respiratory Medicine, Lushan Rehabilitation and Recuperation Center of Chinese PLA/Former 171 Hospital of PLA, Jiangxi Jiujiang 332000,China）
关键词:
微小RNA-23a; 微小RNA-29a; 非小细胞肺癌; 靶向治疗
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.02.013
文献标志码:
A
摘要:
目的　探究非小细胞肺癌（non - small cell lung cancer，NSCLC）患者血清微小RNA（miR）-23a，miR-29a 水平表达对靶向治疗效果的预测价值。方法　选取2015 年12 月～ 2019 年6 月解放军庐山康复疗养中心收治的NSCLC 患者102 例为观察组，选择同期该院健康体检者102 例为对照组。所有NSCLC 患者进行靶向治疗并分析其临床疗效；采用实时荧光定量PCR（quantitative real-time PCR，qRT-PCR）法检测血清miR-23a，miR-29a 表达水平；采用受试者工作特征曲线（receiver operating characteristic curves，ROC曲线）分析血清miR-23a，miR-29a 水平对靶向治疗效果的预测价值。结果　观察组血清miR-23a（1.26±0.31）和miR-29a（1.35±0.42）表达水平均明显高于对照组（0.98±0.28 和1.01±0.30），差异有统计学意义（t=6.770，6.653，均P ＜ 0.05）。血清miR-23a 和miR-29a 表达水平均与NSCLC 患者临床分期、分化程度有关（t=2.128，2.127，均P ＜ 0.05）。102 例NSCLC 患者经治疗后，完全缓解11 例，部分缓解39 例，病情稳定31 例，疾病进展21 例，总有效（完全缓解+ 部分缓解）50 例（49.02%），无效（病情稳定+ 疾病进展）52 例（50.98%）。治疗后，NSCLC 患者血清miR-23a（1.08±0.22）和miR-29a（1.11±0.31）表达水平均明显低于治疗前（1.26±0.31 和1.35±0.42），差异均有统计学意义（t=4.782，4.643，均P ＜ 0.05），且治疗有效患者血清miR-23a（1.05±0.21）和miR-29a（1.08±0.28）表达水平均明显低于治疗无效患者（1.20±0.29 和1.27±0.31），差异均有统计学意义（t=2.982，3.244，均P ＜ 0.05）；血清miR-23a 和miR-29a 及二者联合预测靶向治疗效果的曲线下面积分别为0.688，0.768 和0.821，敏感度分别为72.0%，66.0% 和94.0%，特异度分别为63.5%，78.8% 和55.8%。结论　NSCLC 患者血清miR-23a 和miR-29a 表达水平均升高，但靶向治疗后二者表达水平均降低，检测二者水平有助于预测NSCLC 患者靶向治疗效果。
Abstract:
Objective　To explore the predictive value of serum microRNA (miR) - 23a and miR-29a levels in patients with nonsmall cell lung cancer (NSCLC) for targeted therapy. Methods　A total of 102 cases of NSCLC patients admitted to Lushan Rehabilitation and Recuperation Center of Chinese PLA from December 2015 to June 2019 were selected as the observation group, and 102 cases of healthy people in the hospital during the same period were selected as the control group. All NSCLC patients were treated with targeted therapy and the clinical efficacy was analyzed.The expression levels of miR-23a and miR-29a in serum were detected by real-time fluorescence quantitative PCR (qRT-PCR). Receiver operating characteristic curve (ROC curve) was used to analyze the predictive value of serum miR-23a and miR-29a levels for targeted therapy. Results　The levels of serum miR-23a (1.26 ± 0.31) and miR-29a (1.35 ± 0.42) in the observation group were significantly higher than those in the control group (0.98 ± 0.28 and 1.01 ± 0.30), the difference was statistically significant (t = 6.770，6.653, all P < 0.05).The expression levels of miR-23a and miR-29a were correlated with clinical stage and differentiation degree of NSCLC patients (t=2.128，2.127，all P < 0.05).After treatment, there were 11 cases of complete remission, 39 cases of partial remission, 31 cases of stable disease, 21 cases of disease progression, 50 cases (49.02%) of total effective (complete remission + partial remission), 52 cases of ineffective (stable disease + disease progression) (50.98%), and after treatment, the levels of serum miR- 23a (1.08 ± 0.22) and miR-29a (1.11 ± 0.31) in NSCLC patients were significantly lower than those before treatment (1.26 ± 0.31 and 1.35 ± 0.42), the difference was statistically significant (t = 4.782，4.643, all P < 0.05), and the levels of serum miR- 23a (1.05 ± 0.21) and miR-29a (1.08 ± 0.28) in patients with effective treatment were significantly lower than those in patients with ineffective treatment (1.20 ± 0.29 and 1.27 ± 0.31), the difference was statistically significant (t =2.982，3.244, all P<0.05).The area under the curve of serum miR-23a, miR-29a and their combination were 0.688, 0.768 and 0.821, respectively, with sensitivity of 72.0%, 66.0% and 94.0%, and specificity of 63.5%, 78.8% and 55.8%, respectively. Conclusion　The levels of serum miR-23a and miR-29a in patients with NSCLC were significantly increased, but they were significantly decreased after targeted therapy. Detection of the two levels is helpful to predict the effect of targeted therapy in patients with NSCLC.

参考文献/References:

[1] 邝美华, 陈意珊, 石亚玲. 血小板与淋巴细胞比值对非小细胞肺癌预后评估的Meta 分析[J]. 现代检验医 学杂志, 2018, 33(3): 112-116. KUANG Meihua, CHEN Yishan, SHI Yaling. Prognostic value of platelet to lymphocyte ratio in nonsmall cell lung cancer:a meta-analysis [J]. Journal of Modern Laboratory Medicine, 2018, 33(3): 112-116.
[2] YE Zaiting, FANG Bingmu, PAN Jiongwei, et al. MiR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1[J]. Oncol Rep, 2017, 37(6):3244-3252.,
[3] MEI Yongcheng, SI Jinchun, WANG Yun, et al. Long noncoding RNA GAS5 suppresses tumorigenesis by inhibiting miR-23a expression in non-small cell lung cancer[J]. Oncology Research, 2017, 25(6): 1027-1037.
[4] 郝艳萍, 王光．非小细胞肺癌患者血浆miR-499 与miR-23a 表达及其检测意义[J]．临床肺科杂志, 2018, 23(2):199-202． HAO Yanping, WANG Guang. MiR-499 and miR-23 expression in NSCLC patients and its clinical value [J]. Journal of Clinical Pulmonary Medicine, 2018, 23(2): 199-202.
[5] 孟祥磊, 赖青云, 罗耀玲, 等．miR-23a 在肺癌进程 中的作用[J]. 赣南医学院学报, 2018, 38(11): 1165- 1168. MENG Xianglei, LAI Qingyun, LUO Yaoling, et al. The role of miR-23a in lung cancer progression [J]. Journal of Gannan Medical University, 2018, 38(11): 1165-1168.
[6] 李维青, 姜福胜, 李志田, 等．miR-29a 靶向调控 PDGFB 促进非小细胞肺癌细胞凋亡[J]．基因组学 与应用生物学, 2020, 39(3): 1301-1306. LI Weiqing, JIANG Fusheng, LI Zhitian, et al. MiR- 29a promotes apoptosis in non-small cell lung cancer cells by targeting PDGFB [J]. Genomics and Applied Biology, 2020, 39(3): 1301-1306.
[7] DUFFAUD F, THERASSE P. New guidelines to evaluate the response to treatment in solid tumors[J]. Bulletin du Cancer, 2000, 87(12): 881-886.
[8] 蒋海兵．血清ProGRP 和NSE 检测在小细胞肺癌诊 断和放化疗监测中的价值[J]. 现代检验医学杂志, 2018, 33(6): 153-156. JIANG Haibing. Value of serum proGRP and NSE detection in the diagnosis of small cell lung cancer and the monitoring of radiotherapy and chemotherapy [J]. Journal of Modern Laboratory Medicine, 2018, 33(6): 153-156.
[9] 陈天才, 蒋玮, 曾爱屏, 等．EGFR 敏感突变型 NSCLC 患者血清CEA 水平对靶向治疗疗效预测价 值分析[J]. 中华肿瘤防治杂志, 2018, 25(12): 877- 882. CHEN Tiancai, JIANG Wei, ZENG Aiping, et al. Observation of serum carcinoembryonic antigen level change in non-small cell lung cancer with EGFR sensitive mutation treated with icotinib hydrochloride [J]. Chinese Journal of Cancer Prevention and Treatment, 2018, 25(12): 877-882.
[10] 徐安平．非小细胞肺癌晚期靶向药物治疗中血清肿 瘤标志物预测疗效的临床意义[J]. 湖南师范大学学 报( 医学版), 2018, 15(3): 129-132. XU Anping. Clinical significance of serum tumor markers in predicting the efficacy of targeted drug therapy for advanced non-small cell lung cancer [J]. Journal of Hunan Normal University(Medical Science), 2018, 15(3): 129-132.
[11] CHIEN M H, LEE W J, YANG Y C, et al. KSRP suppresses cell invasion and metastasis through miR- 23a-mediated EGR3 mRNA degradation in non-small cell lung cancer[J]. Biochimica et Biophysica Acta- Gene Regulatory Mechanisms, 2017, 1860(10): 1013- 1024.
[12] 韩学利. 多层螺旋CT 配合血清miR-23a, miR31 及 miR-155 检测用于肺癌诊断的敏感性与特异性探讨 [J]. 实用医院临床杂志, 2018, 15(6): 251-253. HAN Xueli. Sensitivity and specificity of MSCT combined with serum miR-23a,miR31 and miR-155 in diagnosis of lung cancer [J]. Practical Journal of Clinical Medicine, 2018, 15(6): 251-253.
[13] HETTA H F, ZAHRAN A M, SHAFIK E A, et al. Circulating miRNA-21 and miRNA-23a expression signature as potential biomarkers for early detection of Non-Small-Cell lung cancer[J]. MicroRNA (Shariqah, United Arab Emirates), 2019, 8(3): 206-215.
[14] 何嵘, 马业罡, 刘宏旭.miR-23a/b 在非小细胞肺 癌的表达及临床意义[J]. 解剖科学进展, 2017, 23(1):61-64. HE Rong, MA Yegang, LIU Hongxu. Expression and clinical significance of miR-23a/b in non small cell lung cancer [J]. Progress of Anatomical Sciences, 2017, 23(1): 61-64.
[15] CHEN Xialin, ZHU Hong, YE Wa n l i , e t a l . MicroRNA-29a enhances cisplatin sensitivity in non-small cell lung cancer through the regulation of Rev3L[J]. Molecular Medicine Reports, 2019, 19(2): 831-840.
[16] MULUHNGWI P, KRISHNA A, VITTITOW S L, et al. Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells[J]. Cancer Letters, 2017, 388(1): 230-238.
[17] 梁媛, 冯洋洋, 李琳琳, 等．MicroRNA-29a 靶向抑 制PTEN 基因诱导非小细胞肺癌细胞上皮间质转化 的机制研究[J]. 现代肿瘤医学, 2018, 26(5): 653-659. LIANG Yuan, FENG Yangyang, LI Linlin, et al. MicroRNA-29a promotes epithelial -mesenchymal transition in non -small cell lung cancer through downregulating PTEN gene expression [J]. Journal of Modern Oncology, 2018, 26(5): 653-659.
[18] LIU M, ZENG X, LU Y X, et al. Study on molecular mechanism of miRNA-29a in promoting proliferation and invasion of non-small-cell lung cancer by inhibiting MTSS1[J]. European Review for Medical and Pharmacological Sciences, 2018, 22(17): 5531-5538.
[19] 刘文秀, 曹博, 杨娟, 等．循环miR-29a 和miR-150 与非小细胞肺癌胸部放射治疗剂量的相关性[J]. 现 代肿瘤医学, 2018, 26(5): 708-712. LIU Wenxiu, CAO Bo, YANG Juan, et al. Study on the correlation between circulating miR-29a,miR-150 and delivered dose in radiotherapy for non-small cell lung cancer [J]. Journal of Modern Oncology, 2018, 26(5): 708-712.
[20] HAN Zhijun, ZHOU Xiaoyun, LI Shanqing, et al. Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway[J]. Oncol Rep,2017, 38(5):3064-3070.

备注/Memo

备注/Memo:
作者简介：胡鑫（1979-），男，本科，主治医师，研究方向：呼吸系统疾病，E-mail: hx332000@163.com。
更新日期/Last Update: 1900-01-01